{"nctId":"NCT00535730","briefTitle":"ZOSTAVAX™ Administered Concomitantly With PNEUMOVAX™ 23 (V211-012)(COMPLETED)","startDateStruct":{"date":"2007-06"},"conditions":["Herpes Zoster","Pneumococcal Infection"],"count":473,"armGroups":[{"label":"1","type":"PLACEBO_COMPARATOR","interventionNames":["Biological: Zoster Vaccine, Live, (Oka-Merck), ZOSTAVAX™","Biological: Comparator: placebo (concomitant-vaccine matched)"]},{"label":"2","type":"EXPERIMENTAL","interventionNames":["Biological: Zoster Vaccine, Live, (Oka-Merck), ZOSTAVAX™","Biological: Pneumococcal Vaccine, Polyvalent (23-valent), PNEUMOVAX™ 23"]}],"interventions":[{"name":"Zoster Vaccine, Live, (Oka-Merck), ZOSTAVAX™","otherNames":["ZOSTAVAX™"]},{"name":"Comparator: placebo (concomitant-vaccine matched)","otherNames":[]},{"name":"Pneumococcal Vaccine, Polyvalent (23-valent), PNEUMOVAX™ 23","otherNames":["PNEUMOVAX™ 23"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* 60 years of age or older\n* Stable underlying conditions\n* Postmenopausal if female\n* Afebrile\n\nExclusion Criteria:\n\n* Previously vaccinated with either vaccine\n* Immune deficiency\n* History of allergy to components in either vaccine\n* Concomitant antiviral therapy","healthyVolunteers":true,"sex":"ALL","minimumAge":"60 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Geometric Mean Titer (GMT) of Varicella-zoster Virus (VZV) Antibody Responses at 4 Weeks Postvaccination","description":"GMT of the VZV antibody responses at 4 weeks postvaccination in subjects who receive ZOSTAVAX™ concomitantly with PNEUMOVAX™ 23 and those who receive ZOSTAVAX™ and PNEUMOVAX™ 23 nonconcomitantly.\n\n\\*gpELISA = glycoprotein enzyme-linked immunosorbent assay","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"448.5","spread":null},{"groupId":"OG001","value":"371.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Safety and Tolerability of Both Vaccines When Administered Concomitantly.","description":"All adverse events were analyzed including serious adverse events; injection-site adverse events; Vaccination Report Card prompted systemic adverse events, including varicella-like rashes or herpes zoster-like rashes; all other systemic adverse events.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"141","spread":null},{"groupId":"OG001","value":"136","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74","spread":null},{"groupId":"OG001","value":"70","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Fold Rise (GMFR) of the Varicella-zoster Virus (VZV) Antibody Responses From Day 1 to 4 Weeks Postvaccination.","description":"GMFR of the VZV antibody response from prevaccination to Week 4 postvaccination in subjects who receive ZOSTAVAX™ concomitantly with PNEUMOVAX™ 23.\n\ngpELISA = glycoprotein enzyme-linked immunosorbent assay.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Titer (GMT) of the Pneumococcal Polysaccharide (PnPs) Serotype 3 Antibody Response at 4 Weeks Postvaccination.","description":"GMT of the PnPs serotype 3 antibody response at 4 weeks postvaccination in subjects who receive ZOSTAVAX™ concomitantly with PNEUMOVAX™ 23 and those who receive ZOSTAVAX™ and PNEUMOVAX™ 23 nonconcomitantly.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":null},{"groupId":"OG001","value":"1.1","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Titer (GMT) of the Pneumococcal Polysaccharide (PnPs) Serotype 14 Antibody Response at 4 Weeks Postvaccination.","description":"GMT of the PnPs serotype 14 antibody response at 4 weeks postvaccination in subjects who receive ZOSTAVAX™ concomitantly with PNEUMOVAX™ 23 and those who receive ZOSTAVAX™ and PNEUMOVAX™ 23 nonconcomitantly.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.5","spread":null},{"groupId":"OG001","value":"25.7","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Titer (GMT) of the Pneumococcal Polysaccharide (PnPs) Serotype 19A Antibody Response at 4 Weeks Postvaccination.","description":"GMT of the PnPs serotype 19A antibody response at 4 weeks postvaccination in subjects who receive ZOSTAVAX™ concomitantly with PNEUMOVAX™ 23 and those who receive ZOSTAVAX™ and PNEUMOVAX™ 23 nonconcomitantly.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.5","spread":null},{"groupId":"OG001","value":"10.5","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Titer (GMT) of the Pneumococcal Polysaccharide (PnPs) Serotype 22F Antibody Response at 4 Weeks Postvaccination.","description":"GMT of the PnPs serotype 22F antibody response at 4 weeks postvaccination in subjects who receive ZOSTAVAX™ concomitantly with PNEUMOVAX™ 23 and those who receive ZOSTAVAX™ and PNEUMOVAX™ 23 nonconcomitantly.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","spread":null},{"groupId":"OG001","value":"2.5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4},"commonTop":["Pain (PNEUMOVAX™ 23 injection site)","Erythema (ZOSTAVAX™ injection site)","Pain (ZOSTAVAX™ injection site)","Swelling (ZOSTAVAX™ injection site)","Swelling (PNEUMOVAX™ 23 injection site)"]}}}